AMRUTANJAN HEALTH CARE
							
							
								
								
									
										
											| BSE ticker code | 590006 | 
										
											| NSE ticker code | AMRUTANJAN | 
										
											| Major activity | Pharmaceuticals | 
										
											| Managing Director | Sambhu Prasad Sivalenka | 
										
											| Equity capital | Rs. 2.92 crore; FV Re. 01 | 
										
											| 52 week high/low | Rs. 1026 / Rs. 472 | 
										
											| CMP | Rs. 832.85 | 
										
											| Market Capitalisation | Rs. 2523.54 crore | 
										
											| Recommendation | Accumulate at declines | 
									
								 
							 
							Going beyond its legendary balm
							
								mrutanajan Health Care is an Indian pharmaceutical company engaged in the manufacture of
								ayurvedic
								health care products and beauty products. The company has
								diversified into information technology and the food business.
								Amrutanjan Infotech is engaged in IT services and business
								process outsourcing. Through acquisition of Siva’s Soft Drink
								Pvt Ltd, a Chennai-based company, it also started manufacturing fruit juices under the
								brand
								name ‘Fruitnick’. The company is internationally known for its Amrutanjan
								balm. It is growing slowly but steadily
								on the financial front and its prospects
								ahead are quite healthy for investors.
							
							
								Consider:
							
							
								
									- 
										The company, mainly
										known for its balm – a headache pain
										remover – for the last 100 years is a
										household name for this product.
									
- 
										The company is growing but
										very slowly. During the last five years
										its sales turnover has steadily increased from Rs. 219.63 crore
										in the fiscal 2017 to Rs. 332.84 crore in the fiscal 2021 with
										the operating profit moving up from Rs. 29.44 crore to Rs.
										74.75 crore and the profit at net level inching up from Rs.
										22.35 crore to Rs. 61.19 crore respectively during this five
										year period. The company's balance sheet is very healthy with
										strong financial position, its reserves at the end of March 31,
										2021 standing at Rs. 212.64 crore - over 71 times its tiny
										equity capital of Rs. 2.92 crore. This is virtually a debt-free
										company with its interest during the fiscal 2021 being a fractional Rs. 50 lakh
										with rising demand for Ayurvedic medicines, the company's margins are on the
										rise.
									
- 
										With a view to achieving 113 per cent of its national sales through the
										e-commerce route, Amrutanjan has
										started investing in digitzation in a big way, building on the
										sales force automation project that was rolled out earlier by
										building a dashboard that seamlessly integrates data flow from
										various sources. Part of the digitization is also to offer its products for sale
										on its corporate website. Today, its products are
										available online on Amazon, Pharmeasy, Netmeds and Apollo.
										At present, the company has recorded sales of around Rs 1.92
										crore through this route and the management wants to raise
										it to around Rs 5 crore in the first instance. Initially, the company would like
										to focus on growing the pain balm, health
										beverages and woman’s hygiene portfolio through this e-commerce route. The
										company is also working on a mobile application on its popular Comfi brand of
										sanitary napkins and related products,
										aimed at serving women in tracking
										menstrual and feminine health.
									
- 
										Amrutanjan has
										planned an aggressive marketing strategy. Accordingly, now it focuses on
										building distribution for its brands with
										the ‘M5K’ plan that targets a vision of
										appointing 5,000 distributors and subdistributors. Over a year ago, the company
										had appointed around 1,000 distributors and sub-distributors, improving direct
										coverage from 3,950 to 4,500 towns. Now, it would
										like to grow its distribution of its products to regions in the western and
										northern zones where its business is relatively weak.
									
- 
										In the meanwhile, the company has extended its product range instead of
										depending only on its pain balm. It launched
										an innovative back pain ‘Rollon’ format which became a runaway success. What is
										more. its competitors were forced to
										copy it. Again, Amrutanjan was the first company to introduce
										a Rs 2 sachet which was later copied by Zandu, its major competitor. The company
										also increased the efficacy of its products by augmenting the menthol content
										and launched a new
										cardboard packaging. All these changes have injected new life
										into the 125-year-old company.
									
- 
										The company has also entered the female hygiene
										category through its Comfy brand of sanitary pads, which is
										positioned as an affordable brand and targets users from semiurban and rural
										India. This is considered a category worth Rs
										1,800-2,000 crore and major players Stayfree and Whisper
										enjoy a big share of this market. Amrutanjan has tremendous
										scope for promoting its product in the semiurban and village segments of th
									
								Shares of the company are quoted
								around Rs 825. We feel this is quite an
								attractive bet. Investors with a long perspective will be able to reap rich harvest
								by investing in this company.
							
							
								PERFORMANCE INDICATORS (Rs. in crore)
							
							
								
									
										
											| Year | Net Sales | Net Profit | EPS (Rs.) | Div (%) | BV (%) | RONW (%) | 
									
									
										
											| 2018-19 | 253.20 | 24.50 | 8.40 | 215.0 | 51.10 | 17.90 | 
										
											| 2019-20 | 261.50 | 154.40 | 8.60 | 210.0 | 54.50 | 16.40 | 
										
											| 2020-21 | 332.84 | 61.12 | 20.90 | 420.0 | 81.80 | 32.60 | 
									
								
							 
						 
						
							
							ADVANCED ENZYME TECHNOLOGIES
							
							
								
								
									
										
											| BSE ticker code | 540025 | 
										
											| NSE ticker code | ADVENZYMES | 
										
											| Major activity | Agricultural Products | 
										
											| Chairman | Vasant Rathi | 
										
											| Equity capital | Rs. 22.36 crore; FV Rs. 02 | 
										
											| 52 week high/low | Rs. 503 / Rs. 297 | 
										
											| CMP | Rs. 348.00 | 
										
											| Market Capitalisation | Rs. 3890.34 crore | 
										
											| Recommendation | Buy at declines | 
									
								 
							 
							Growing global enzyme footprint
							
								Advanced Enzyme Technologies may be a small
								cap but it’s the largest enzyme manufacturing company in India. During the last two
								decades, it has transformed itself into
								a global enzyme powerhouse based on its R&D and tech innovation. It manufactures
								400-plus proprietary products developed from over 68 indigenous enzymes and products.
								The company
								is one of the few manufacturers in
								the world to possess great depth and
								expertise in fermented manufacturing. AET has excellent growth prospects going ahead.
							
							
								Consider:
							
							
								
									- 
										The company caters to diversified industries and verticals like
										human nutrition, animal nutrition and
										bio-processing. It provides its proprietary enzyme products and customized
										enzyme products to various pharmaceutical and nutraceutical
										companies in India, other Asian countries, North America and
										Europe. The company has state-of-the-art manufacturing facilities and R&D
										centres across India, the US and Germany
									
- 
										AET has expanded its operations through the acquisition route. It acquired
										several companies, including CalIndia Foods International (which gave AET a
										direct presence
										in the US), Advanced Supplementary Technologies Corporation (which consolidated
										its presence in the US), JC Biotech
										Pvt Ltd, AEM of Malaysia and Evoxx Technologies GmbH.
										Today, the company has three wholly owned subsidiaries, three
										joint ventures and five step-down subsidiaries, all of which
										help AET service 700 clients spread across 45 countries.
									
- 
										With these acquisitions, the company has made slow
										but steady progress on the financial front. During the last 11
										years, its sales turnover has advanced from Rs 116 crore in
										fiscal 2011 to Rs 502 crore in fiscal 2021, with the operating
										profit growing from Rs 23 crore to Rs 232 crore and the net
										profit inching up from Rs 17 crore to Rs 146 crore during this
										period. The company’s financial position is very strong, with
										reserves at the end of March 2021 standing at Rs 948 crore –
										more than 43 times its equity capital of Rs 22 crore. As its debt
										is negligible (Rs 23 crore), it is virtually a debt-free company.
									
								GLOBAL POTENTIAL
							
							
								From 2022 to 2028, the global
								technical enzymes market is expected to develop at a fast pace, according to the
								latest MarketsandResearch.biz document.
								For the forecast period, the paper
								proposes a marketshare estimation
								in terms of volumes. This study
								looks at the market definition, classifications, applications, engagements and global
								technical enzymes
								enterprise trends.
							
							
								The local evaluation phase reveals the substantial capability of every region in the
								global technical enzymes marketplace collectively with its period and amount. The study
								explains expansion techniques and procedures, estimates,
								production processes and fee structures. It also consists of
								product offerings, revenue evaluation, production capabilities, gross margins and
								numerous different crucial elements
								that effect the profitability of the company involved in the
								market. Advanced Enzymes Technologies will be one of the
								major beneficiaries of this market potential.
							
							
								
									- 
										Prospects ahead are highly promising as enzymes
										are used in a wide variety of industries like human healthcare
										and nutrition, animal nutrition, banking, fruit and vegetable
										processing, brewing and malting, grain processing, protein
										modification, dairy processing, speciality applications and
										textile processing. The management expects sales to cross the
										Rs 1,000-crore mark within the next five years, with a corresponding improvement
										in earnings.
									
- 
										The company’s shareholding is in strong hands, with
										the promoters holding 52.55
										per cent, foreign institutional
										investors (FIIs) 16.27 per
										cent and domestic institutional investors (DIIs) 8.67
										per cent.
									
								CONSOLIDATED PERFORMANCE INDICATORS (Rs. in crore)
							
							
								
									
										
											| Year | Net Sales | Net Profit | EPS (Rs.) | Div (%) | BV (%) | RONW (%) | 
									
									
										
											| 2018-19 | 419.60 | 111.20 | 10.00 | 30.0 | 66.60 | 18.00 | 
										
											| 2019-20 | 444.00 | 129.30 | 11.60 | 30.0 | 75.20 | 17.00 | 
										
											| 2020-21 | 501.84 | 145.69 | 13.00 | 45.0 | 91.70 | 16.10 | 
									
								
							 
						 
						
							
							ADC INDIA COMMUNICATIONS
							
							
								
								
									
										
											| BSE ticker code | 522074 | 
										
											| NSE ticker code | ELGIEQUIP | 
										
											| Major activity | Industrial Machinery | 
										
											| Managing Director | Jairam Varadaraj | 
										
											| Equity capital | Rs. 31.69 crore; FV Re. 01 | 
										
											| 52 week high/low | Rs. 423 / Rs. 173 | 
										
											| CMP | Rs. 306.50 | 
										
											| Market Capitalisation | Rs. 9713.26 crore | 
										
											| Recommendation | Buy at declines | 
									
								 
							 
							Financials poor, potential high
							
								Headquartered in Bengaluru, ADC India
								Communications (formerly known as Krone Communications)
								is a leading player in broadband connectivity and provides
								connection solutions for wireline, wireless, cable broadcast
								and enterprise networks. The company is an undisputed leader
								in providing network infrastructure
								products and services that support
								its customers in migration to next
								generation networks. It plays a crucial role in enabling customers to
								deliver dynamic video, data, voice
								and wireless services that are increasingly essential to telcos, enterprises and
								infrastructure providers.
								Despite its important role, ADC’s
								shares are quoted at below intrinsic
								value and hence are worth buying.
							
							
								Consider:
							
							
								
									- 
										The telecom sector continues to be at the epicentre
										for growth, innovation and disruption for virtually any industry. According to a
										study, smartphones today account for two
										out of every three mobile connections globally. Mobile devices and related
										broadband connectivity continue to be more
										and more embedded in our daily life and are key in driving
										the momentum around key trends like video streaming, Internet
										of Things (IoT) and mobile payments. This trend is a key
										growth driver for ADC India Communications.
									
- 
										The company expects higher growth in the medium
										term driven by demand from infrastructure projects, the defence sector,
										e-commerce, hospitality, education, IT/ITeS and
										government projects. The company expects growth in the fiber business vis-à-vis
										copper due to the large infrastructure
										corridors, the national fiber optic network, and the ‘Digital
										India’ and ‘Smart City’ initiatives.
									
- 
										ADC has introduced new products like a fiber and
										copper patch lock system, which helps customers look at an
										additional level of physical security in critical connectivity requirements, and
										also continues its work in supporting highdensity fiber requirements for
										co-locations with better manageability feature
									
- 
										Communications service providers across the globe
										are continuing their rapid migration to next-generation networks that can
										deliver reliable
										broadband services over any device
										anytime, anywhere. At the same
										time, high speed enterprise networks
										and data centres continue to be built
										to meet the challenge of transmitting
										and storing the vast amounts of information critical for success in modern
										business. The need for ubiquitous access, scalable bandwidth and
										robust, reliable connectivity is no different for a carrier, cable company
										or enterprise. All depend on ADC's
										network infrastructure expertise to help them design and deploy high-speed wired
										networks offering dynamic video, data,
										and voice to businesses and consumers.
									
- 
										The company has also introduced new products
										that would cater to the telecom market such as fiber-to-antenna and
										copper-to-antenna products that will help support upcoming 4G projects. It has
										also introduced outdoor
										environment enclosures/cable assembly products to support
										the security and surveillance market and continues its focus
										on a standard-compliant product portfolio to increase its geographical reach
									
- 
										The company’s financial performance so far is not
										that heart-warming. During the last five years, its sales have
										declined marginally from Rs 62.32 crore in fiscal 2017 to Rs
										126.60 crore in fiscal 2021, with the operating profit inching
										up fractionally from Rs 3.63 crore to Rs 4.84 crore and the
										net profit declining from Rs 3.82 crore to Rs 3.62 crore during
										this period. A plus point for the company is that it is a debtfree entity and is
										regular in payment of dividends, the rate for
										the last year being 25 per cent.
									
								According to research analysts, at the
								current price of Rs. 380, the scrip is undervalued on the basis of its intrinsic value,
								which is Rs 522 as determined by the median of 3 historical modes.
							
							
								PERFORMANCE INDICATORS (Rs. in crore)
							
							
								
									
										
											| Year | Net Series | Net Profit | EPS (Rs.) | Div (%) | BV (%) | RONW (%) | 
									
									
										
											| 2018-19 | 85.62 | 5.86 | 12.70 | ---- | 110.00 | 7.82 | 
										
											| 2019-20 | 78.13 | 3.80 | 8.30 | 20.0 | 87.30 | 9.63 | 
										
											| 2020-21 | 59.86 | 3.61 | 7.80 | 25.0 | 98.80 | 8.69 |